Norditropin Flexpro (Somatropin)

Somatropin binds to growth hormone receptors on cell surfaces, activating intracellular JAK2‑STAT5 signaling. This triggers the liver to produce insulin‑like growth factor‑1 (IGF‑1), which drives bone growth, protein synthesis, lipolysis and overall anabolic activity, thereby supporting normal stature and metabolic functions.

The dose of Norditropin Flexpro is individualized. A qualified prescriber determines the amount, frequency and duration based on the patient’s age, weight, IGF‑1 levels, underlying condition and growth response, following approved clinical guidelines.

Safety data for somatropin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Norditropin Flexpro is a pre‑filled pen delivering somatropin, similar to other recombinant growth hormones such as Genotropin or Humatrope. Differences lie mainly in device convenience, formulation stability and specific storage requirements, while the active molecule and clinical efficacy remain comparable.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original packaging until use, and any unused portion should be discarded after the recommended in‑use period indicated on the label.

Norditropin Flexpro is supplied as a solution for injection in a pre‑filled pen. It is administered subcutaneously, typically into the thigh, abdomen or buttock, using the pen’s dosing mechanism as instructed by the prescribing clinician.

Serious risks include intracranial hypertension, slipped capital femoral epiphysis, new‑onset diabetes or worsening glucose control, allergic reactions (including anaphylaxis), and potential tumor recurrence in patients with a history of malignancy. Prompt medical evaluation is required if any of these occur.

Norditropin Flexpro is contraindicated in individuals with active malignancy, known hypersensitivity to somatropin or any excipients, and in patients with uncontrolled diabetes where glucose monitoring is not feasible. Use is also not recommended for those with acute critical illness unless specifically indicated.